Furthermore, continuation therapy that incorporates cycling EGFR TKI treatment may suppress the outgrowth of aggressive drug resistant clones that can be associated with the clinical phenomenon of tumor flare upon discontinuation of EGFR TKI therapy [44]. Here, EGFR is linked to neoplasm.